EMD Millipore, the Life Science division of Merck KGaA, Darmstadt, Germany, introduced Parteck SRP 80, a new functional excipient for oral sustained-release formulations. Parteck SRP 80 is a polyvinyl alcohol (PVA) based excipient specifically designed for modified-release applications, for optimisation of pharmacokinetics and pharmacodynamics as well as the bioavailability of actives.

The new excipient is fully synthetic, ensuring batch-to-batch and performance consistency and facilitating quality by design (QbD) and validation processes.

Suitable for direct compression processes, Parteck SRP 80 allows for fast, easy and efficient formulation development as well as production processes. Parteck SRP 80 is compliant with European Pharmacopoeia (Ph. Eur.), United States Pharmacopoeia (USP) and Japanese Pharmacopoeia Excipients (JPE) and will be part of EMD Millipore’s Emprove programme to facilitate regulatory filing and registration processes.

“Pharmaceutical excipients play an essential role in the development of safe and effective medicines,” said Andrew Bulpin, executive vice president of process solutions, EMD Millipore.

“Parteck SRP 80 represents a new choice for customers looking to formulate prolonged release oral dosage forms with reliable performance profiles as well as robust and cost efficient production processes, which can translate into improved patient safety and compliance.”